CRTH2拮抗剂OC 000459对哮喘患者肺功能的影响：一项随机对照试验的荟萃分析。

The impact of CRTH2 antagonist OC 000459 on pulmonary function of asthma patients: a meta-analysis of randomized controlled trials.

作者信息

Tang Meng, Zhang Yan, Chen Ying

机构信息

Department of Respiration, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang, China.

Department of Radiology, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang, China.

出版信息

Postepy Dermatol Alergol. 2021 Aug;38(4):566-571. doi: 10.5114/ada.2020.92296. Epub 2020 Jan 31.

DOI:10.5114/ada.2020.92296

PMID:34658695

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8501448/

Abstract

INTRODUCTION

The chemoattractant receptor expressed on T-helper (Th) type 2 cells (CRTH2) antagonist OC 000459 showed the potential in improving pulmonary function of asthma patients.

AIM

We conducted a systematic review and meta-analysis to explore the impact of CRTH2 antagonist OC 000459 on pulmonary function for asthma.

MATERIAL AND METHODS

PubMed, Embase, Web of science, EBSCO, and Cochrane library databases were systematically searched. This meta-analysis included randomized controlled trials (RCTs) assessing the effect of CRTH2 antagonist OC 000459 on pulmonary function for asthma. Two investigators independently searched articles, extracted data, and assessed the quality of included studies.

RESULTS

Four RCTs were included in the meta-analysis. Overall, compared with the control intervention for asthma patients, CRTH2 antagonist OC 000459 could significantly improve FEV (SMD = 0.22; 95% CI: 0.02-0.42; = 0.03), peak expiratory flow (SMD = 0.22; 95% CI: 0.01-0.42; = 0.04) and reduce the respiratory tract infection (RR = 0.47; 95% CI: 0.26-0.85; = 0.01), but revealed no remarkable effect on predicted FEV (SMD = 0.14; 95% CI: -0.18 to 0.45; = 0.39), or treatment-related adverse events (RR = 0.84; 95% CI: 0.52-1.36; = 0.48).

CONCLUSIONS

CRTH2 antagonist OC 000459 might be effective and safe to improve pulmonary function in asthma patients.

摘要

引言

2型辅助性T细胞（Th2）上表达的趋化因子受体（CRTH2）拮抗剂OC 000459显示出改善哮喘患者肺功能的潜力。

目的

我们进行了一项系统评价和荟萃分析，以探讨CRTH2拮抗剂OC 000459对哮喘患者肺功能的影响。

材料与方法

系统检索了PubMed、Embase、Web of science、EBSCO和Cochrane图书馆数据库。这项荟萃分析纳入了评估CRTH2拮抗剂OC 000459对哮喘患者肺功能影响的随机对照试验（RCT）。两名研究人员独立检索文章、提取数据并评估纳入研究的质量。

结果

荟萃分析纳入了四项RCT。总体而言，与哮喘患者的对照干预相比，CRTH2拮抗剂OC 000459可显著改善第一秒用力呼气容积（标准化均数差[SMD]=0.22；95%置信区间[CI]：0.02 - 0.42；P=0.03）、呼气峰值流速（SMD = 0.22；95% CI：0.01 - 0.42；P = 0.04），并减少呼吸道感染（相对危险度[RR]=0.47；95% CI：0.26 - 0.85；P = 0.01），但对预计第一秒用力呼气容积（SMD = 0.14；95% CI：-0.18至0.45；P = 0.39）或治疗相关不良事件（RR = 0.84；95% CI：0.52 - 1.36；P = 0.48）无显著影响。